bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.79 · Revenue $108.53M · 1 analysts
Est. EPS $-8.56 · Revenue $409.44M · 1 analysts
Est. EPS $-6.86 · Revenue $277.00M · 1 analysts
Est. EPS $-1.56 · Revenue $333.00M · 1 analysts
EPS $-1.01 · Revenue $12.39M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $83.8M | +184.1% | +0.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-240.7M | -13.6% | -1.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -6.6% | +51.3% | +67.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -322.7% | +61.0% | +32.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -287.2% | +60.0% | -0.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-262.6M | -7.6% | +12.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -313.4% | +62.1% | +13.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -1136.0% | -769.0% | +71.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.48x | -65.8% | +15.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $460.2M | -25.7% | -35.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -24.84 vs -24.55 | -1.2% | -2.98 vs -3.29 | +9.4% |
| Revenue Surprise | $83.8M vs $73.2M | +14.5% | $38.7M vs $38.7M | -0.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 2, 2025 | Vittiglio Joseph | officer: Chief Business & Legal Officer | Common Stock | A | 2,500 | $3.00 |
| Jun 2, 2025 | Vittiglio Joseph | officer: Chief Business & Legal Officer | Common Stock | D | 2,500 | $3.00 |
| Jun 2, 2025 | Agwunobi John O | director | Common Stock | D | 1,245 | $3.00 |
| Jun 2, 2025 | Vachon Mark | director | Common Stock | D | 1,245 | $3.00 |
| Jun 2, 2025 | Colvin Richard A | officer: Chief Medical Officer | Common Stock | A | 2,500 | $3.00 |
Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to bluebird bio's Third Quarter 2024 Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded. I'll now hand the conference over to your host, Courtney O'Leary, Director of Investor Relations. Please go ahead. Courtney O'Leary: Good morning, everyone, and thank you for joining our third quarter 2024 results call today. My name is Courtney O'Leary, Director of Investor Relations at bluebird bio. Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position in addition to statements of the company's plans, expectations or intentions regarding regulatory progress, commercialization plans and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com. With that, I will turn it over to bluebird bio's CEO, Andrew Obenshain. Andrew Obenshain: Thank you, Courtney, and thank you everyone for joining our call this morning. As a gene therapy pioneer and the only standalone commercial-stage gene therapy company in the market today, we have built what we believe to be an unparalleled foundation over the past two years since our first FDA approval with a robust qualified treatment center network, proven access and reimbursement and demonstrated demand for our therapies from both patients and from providers. Today, we are seeing the results of those efforts. Since we reported our Q2 earnings in August, we have more than doubled patient starts from 27 to 57 across our portfolio. We initiated steps to reduce our cash operating expenses by 20% in Q3 2025, and we've laid out a roadmap to financial stability and cash flow breakeven in the second half of next year should we accomplish our goal of securing additional cash resources. On today's call, Tom Klima, Chief Commercial and Operating Officer, will provide updates on the commercial launches of LYFGENIA, ZYNTEGLO and SKYSONA. Then, bluebird's CFO, James Sterling, will provide an update and some comments on our recent proxy vote before opening the call for Q&A. I will now hand the call over to Tom. Tom Klima: Thanks, Andrew, and good morning, everyone. We continue to see strong growth in our commercial launches in the third quarter, with clear and established paths to access for our therapies and an …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Andrew Obenshain | President, Chief Executive Officer & Director | USD 746,605 | Male | 1975 | Active |
Richard Colvin | Chief Medical Officer | USD 691,403 | Male | 1967 | Active |
Joseph D. Vittiglio | Chief Legal & Business Officer and Secretary | USD 574,493 | Male | 1972 | Active |
Thomas J. Klima | Chief Commercial & Operating Officer | USD 527,924 | Male | 1972 | Active |
Andrea Walton | Chief People Officer | — | Female | — | Active |
Kasra Kasraian | Senior Vice President of Quality, Regulatory & CMC Sciences | — | Male | — | Active |
Oliver James Sterling | Chief Financial Officer & Principal Accounting Officer | — | Male | — | Active |
Scott Shoemaker | Senior Vice President of Technical Operations | — | Male | — | Active |
Former Blue Foundry Bank customers now have access to full suite of Fulton Bank products, services and financial centers LANCASTER, Pa., July 13, 2026 /PRNewswire/ -- Fulton Financial Corporation (NASDAQ: FULT) ("Fulton") announced the merger of Blue Foundry Bank with and into Fulton Bank, N.A.
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warranted BRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026.
New capability enables multi-site Japanese numbering without external equipment, making full-cloud communications easier to deploy nationwide New capability enables multi-site Japanese numbering without external equipment, making full-cloud communications easier to deploy nationwide
MINNEAPOLIS--(BUSINESS WIRE)---- $MFIN #ActivistInvesting--BIMIZCI Fund LLC, Warnke Investments LLC, ZimCal Asset Management, LLC and Stephen Hodges (collectively, "BIMIZCI" or "we"), long-standing holders of Medallion Financial Corp. (NASDAQ: MFIN) ("Medallion" or the "Company") trust preferred securities and currently the 4th largest institutional stockholder with 500,250 shares, announced today that both leading independent proxy advisory firms, Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Gla.
SAN DIEGO--(BUSINESS WIRE)---- $OWL #BlueOwl--Haeggquist & Eck, LLP Announces Investigation of Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties.
